PROGRAM - MONDAY, MAY 5, 2008

PROGRAM - MONDAY, MAY 5, 2008

7:15AM–8:15 AM ISPOR FORUMS (Open Forum with buffet breakfast)
   
ISPOR PRO - Changing Culture or Language of a Instrument Task Force Forum

Multinational trials - What translations are required, what methodology should be used and what methodology supports pooling the data?

Decision-making tools and rationales for language selection in multinational clinical trial development and considerations for pooling trial data in light of the draft FDA guidance document on PRO development and validation will be presented. For PRO/health-related quality of life (HRQL) researchers and those involved in conducting clinical research, trials and drug development.

  1. How to select the number and specific languages required for translation in a particular country - Tool: a table to help determine which languages are required per country
  2. What methods to use when the same language is required for multiple countries
    Tool: a scenario-based decision tree for adaptation methodologies
  3. Discussion of the issues and evidences around pooling trial data across countries
Moderator: Diane Wild MSc, Director, Oxford Outcomes Ltd, Oxford, UK
Speakers:
Isabelle Mear MA, Managing Director, Mapi Research Institute, Linguistic Validation, Lyon, France; Sonya Eremenco MA, ePRO Manager, United BioSource Corp, Bethesda, MD, USA
ISPOR Patient Registry SIG Forum

Registry Design, Operations, Data & Taxonomy

This session will focus on good research principles, practical design and operational considerations in developing registries and the use of patient registry information as well as the ISPOR Taxonomy of Patient Registries book.

Speakers:
Patient Registry SIG Working Group Chairs: Chris L. Pashos PhD, Vice President and Executive Director, HERQuLES. Abt Associates; Leanne R. Larson MHA Vice President, Registry Consulting, Ovation Research Group / ICON Clinical Research; Annette Stemhagen, DrPH, FISPE, Vice President, Epidemiology and Risk Management, United BioSource Corporation

ISPOR Retrospective Database SIG Forum

What You Need to Know about the ISPOR Digest of International Databases

The ISPOR Digest of International Databases has become an invaluable source of real-world data which is available for health care outcomes researchers internationally. This forum will discuss the benefits of this resource for health care decision makers and ultimately patients. Information will also be presented on the newly revised questionnaire and search and comparison features. Search information is available in word or pdf form. An open forum for attendees will finalize this program.

Speakers:
Carl Asche PhD, Co-Chair, Classification of Databases Working Group, ISPOR Retrospective Database SIG group and Associate Professor, University of Utah, Salt Lake City, Utah, USA;
Gordon Cummins MS, Co-Chair, Classification of Databases Working Group, ISPOR Retrospective Database SIG group and National Account Manager, Surveillance Data Inc., Farmington, MO, USA
8:30AM-8:45AM WELCOME & INTRODUCTION
 

Adrian Levy PhD, Program Co-Chair & Associate Professor, University of British Columbia, Vancouver, Canada;
C. Daniel Mullins PhD,  Program Co-Chair & Professor and Chair, Pharmaceutical Health Services Research Department, University of Maryland School of Pharmacy, Baltimore, MD, USA

8:45AM-9:00AM PRESIDENTIAL ADDRESS
 

Diana BrixnerDiana Brixner PhD
2007-2008 ISPOR President and
Associate Professor and Department Chair, College of Pharmacy,
University of Utah, College of Pharmacy, Salt Lake City, UT, USA
9:00AM-10:15AM FIRST PLENARY SESSION:
  New Evidence on Evidence-Based Technology Assessment in the USA vs. Canada
The requirement for evidence when performing technology assessments is viewed by some as a logical process for making decisions and by others as an impossible hurdle and a moving target. Technology assessment occurs quite differently across public and private payers in Canada and the United States, yet all agree that credible evidence is needed for technology assessment and adoption. Panelists representing public and private payers will discuss how they currently assess evidence and conduct technology assessments and how this may change in the future.
Moderator/Speaker:
Mark Sculpher PhD Mark Sculpher PhD
Professor of Health Economics, Centre for Health Economics, University of York, York, UK

Speakers:
Leslie Levin MB, MD, FRCP, FRCPC Leslie Levin MB, MD, FRCP, FRCPC
Senior Medical, Scientific and Health Technology Advisor and Head, Medical Advisory Secretariat, Ministry of Health and Long-Term Care, Toronto, ON, Canada
Sean Tunis MD, MSc Sean Tunis MD, MSc
Director, Center for Medical Technology Policy, Baltimore, MD, USA
David Yoder PharmD, MBA David Yoder PharmD, MBA
Executive Director, Federal Employee Health Plan Pharmacy Programs, Blue Cross Blue Shield Association, Washington D.C., USA
 
10:15AM-10:45AM BREAK, EXHIBITS & POSTER PRESENTATIONS VIEWING - SESSION I
 
10:45AM-11:45AM PODIUM PRESENTATIONS - SESSION I (5 concurrent session)
 


HEALTH CARE DECISION-MAKER’S CASE STUDIES I

CASE1: AN INTEGRATED PILOT PROJECT UTILIZING AN INTERNAL HTA PROCESS TO SET MEDICAL AND PAYMENT POLICY IN A U.S. COMMERCIAL HEALTH PLAN
Watkins J1, Choudhury S1, Sturm L2, Bresnahan B3, Sullivan S3
1Premera Blue Cross, Mountlake Terrace, WA, USA; 2Formulary Resources, LLC, Issaquah, WA, USA; 3University of Washington, Seattle, WA, USA

CASE 2: DRUG ELUTING STENTS - AN EXAMPLE OF THE TRANSITION FROM EVIDENCE TO POLICY THROUGH THE ONTARIO COMPREHENSIVE APPROACH TO THE DIFFUSION OF HEALTH TECHNOLOGIES
Levin L1, Goeree R2
1Ontario Ministry of Health and Long-Term Care, Toronto, ON, Canada; 2McMaster University, Hamilton, ON, Canada

CASE 3: REVIEWING AND ADAPTING A LOCAL HEALTH TECHNOLOGY ASSESSMENT PROGRAM TO DEPARTMENTS WITHIN A CANADIAN HEALTH REGION
Austen L, Poulin P
Calgary Health Region, Calgary, AB, Canada

Outcomes Research in Canada

CA1: ECONOMIC ANALYSIS OF IMPLANTABLE CARDIOVERTER DEFIBRILLATORS IN THE PRIMARY PREVENTION OF SUDDEN CARDIAC DEATH - A CANADIAN PERSPECTIVE
Deniz B1, Sadri H2
1United BioSource Corporation, Concord, MA, USA, 2Medtronic of Canada Ltd, Toronto, ON, Canada

CA2: THE USE OF RESEARCH ABSTRACTS IN FORMULARY DECISION MAKING BY THE ONTARIO CANCER DRUG APPROVAL COMMITTEE
Weizman A1, Bell C2
1University of Toronto, Toronto, ON, Canada, 2Department of Medicine, St. Michael's Hospital, Toronto, ON, Canada

CA3: A COST-EFFECTIVENESS ANALYSIS OF HEPATITIS C SCREENING AMONG IMMIGRANTS IN CANADA.
Chen W1, Dinner K2, Wong T2, Heathcote J3, Krahn MD3
1University of Toronto, Toronto, ON, Canada, 2Public Health Agency of Canada, Ottawa, ON, Canada, 3University Health Network, Toronto, ON, Canada

CA4: THE EARLY CLINICAL AND ECONOMIC BENEFITS OF ATORVASTATIN IN A CANADIAN SETTING
Merikle E1, Ramos É1, Kuznik A2, Botteman MF3
1Pfizer Canada Inc, Kirkland, QC, Canada, 2Pfizer Inc, New York, NY, USA, 3PharMerit North America LLC, Bethesda, MD, USA

Drug and Health Services Use Research

DH1: FOLLOW-UP VISITS FOR PATIENTS WITH MAJOR DEPRESSIVE DISORDER DURING INITIATION OF ANTIDEPRESSANT TREATMENT
Chen SY, Hansen R, Maciejewski ML
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

DH2: IMPACT OF ADHERING TO LIPID MANAGEMENT NATIONAL GUIDELINE RECOMMENDATIONS ON CARDIOVASCULAR EVENTS AND COSTS IN A MANAGED CARE POPULATION
Balu S1, Simko RJ1, Burge RT1, Quimbo R2, Cziraky MJ2
1Abbott Laboratories, Abbott Park, IL, USA, 2HealthCore, Inc, Wilmington, DE, USA

DH3: THE IMPACT OF DRUG VINTAGE ON PATIENT SURVIVAL: A PATIENT-LEVEL APPROACH USING QUEBEC'S PROVINCIAL HEALTH PLAN DATA
Lichtenberg F1, Van Audenrode M2, Grootendorst P3, Latremouille-Viau D2, Lefebvre P2
1Columbia University, New York, NY, USA, 2Groupe d'analyse, Ltee, Montreal, QC, Canada, 3University of Toronto, Toronto, ON, Canada

DH4: MARKET DISCONTINUATION OF PHARMACEUTICALS IN THE UNITED STATES: ANALYSIS OF NEW DRUGS APPROVED FROM 1980 TO 2007
Qureshi ZP, Szeinbach SL, Seoane-Vazquez E
The Ohio State University, Columbus, OH, USA

Research on Medicare Part D and Reimbursement Policies I

MD1: MEDICARE PART D: EARLY EVIDENCE ON PRESCRIPTION DRUG TREATMENT PATTERNS, HOSPITALIZATION OFFSETS AND MEDICARE SPENDING
Zhang Y1, Newhouse JP2, Hanlon J1, Lave J1, Donohue JM1
1University of Pittsburgh, Pittsburgh, PA, USA, 2Harvard University, Boston, MA, USA

MD2: THE IMPACT OF MEDICARE PART D ON THE PERCENT GROSS MARGIN EARNED BY TEXAS INDEPENDENT PHARMACIES FOR DUAL ELIGIBLE BENEFICIARY CLAIMS
Winegar AL, Shepherd MD, Lawson K, Richards KM
University of Texas at Austin, Austin, TX, USA

MD3: IMPACT OF MEDICARE PART D DOUGHNUT HOLE ON THE USE OF MEDICATIONS BY THERAPEUTIC CLASSES FOR STANDARD BENEFICIARIES
Sun SX, Lee KY
Walgreens Health Services, Deerfield, IL, USA

MD4: IMPACT OF THE MEDICARE MODERNIZATION ACT OF 2003 ON PART B DRUG USE AND SPENDING: A CASE STUDY OF BIOLOGICALS FOR RHEUMATOID ARTHRITIS
Doshi JA, Li P, Puig A
University of Pennsylvania, Philadelphia, PA, USA

Mental Health Outcomes Research

MH1: REAL WORLD ASSOCIATION BETWEEN ANTIPSYCHOTIC TREATMENT AND WEIGHT GAIN IN AN ADOLESCENT POPULATION
Ghate SR1, Said Q2, Rosenblatt LC3, Kim E3, Pikalov A4, Brixner D1
1The University of Utah College of Pharmacy, Salt Lake City, UT, USA, 2University of Arkansas for Medical Sciences, Little Rock, AR, USA, 3Bristol-Myers Squibb, Plainsboro, NJ, USA, 4Otsuka America Pharmaceuticals, Rockville, MD, USA

MH2: ECONOMIC AND CLINICAL CONSEQUENCES ASSOCIATED WITH POTENTIAL DRUG-DRUG INTERACTIONS BETWEEN ANTIPSYCHOTICS AND CONCOMITANT MEDICATIONS IN PATIENTS WITH SCHIZOPHRENIA
Guo JJ1, Kelton CM1, Patel NC1, Wu JH2, Jing Y1, Fan H3, Keck P1
1University of Cincinnati, Cincinnati, OH, USA, 2Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 3Covance Inc, Sun Prairie, WI, USA

MH3: WORK ABSENTEEISM AND BED DAYS IN CHRONIC MEDICAL DISORDER PATIENTS WITH AND WITHOUT DEPRESSION IN THE UNITED STATES, 2004-2005
Sankaranarayanan J, Smith LM, Meza J, Burke WJ
University of Nebraska Medical Center, Omaha, NE, USA

MH4: TREATMENT COST AND COMORBIDITIES ASSOCIATED WITH OBESITY AMONG CHILDREN AND ADOLESCENTS WITH BIPOLAR DISORDER
Guo JJ1, Kelton CM1, Jing Y1, Patel NC2
1University of Cincinnati, Cincinnati, OH, USA, 2University of Georgia, Augusta, GA, USA

 
12:00PM-1:00PM PODIUM PRESENTATIONS - SESSION II (5 concurrent session)
   

HEALTH CARE DECISION-MAKER’S CASE STUDIES II

CASE 4: THE IMPACT OF THE PROJECT OF ENHANCING COVERAGE RATE FOR PATIENTS WITH CANCER
Lee SM, Nam MH, Yoon SH, Kim BY, Choi MR, Cho HS, Lee KD
Health Insurance Review & Assessment Services, Seoul, South Korea

CASE 5: THE CENTER FOR DRUG POLICY: PARTNERS HEALTH CARE
Reddy P1, Yeh Y1, Clapp M2, Churchill W3
1Partners Healthcare, Charlestown, MA, USA; 2 Massachusetts General Hospital, Boston, MA, USA; 3 Brigham and Women's Hospital, Boston, MA, USA

CASE 6: THE USE OF AN EVIDENCE-BASED PRACTICE STRATEGY TO IMPROVE QUALITY IN THE ACUTE CARE SETTING
Mutnick AH, Wong PK, Hanseman DJ
Mercy Health Partners, Southwest Ohio, Cincinnati, OH, USA

Cancer Outcomes Research

CN1: TRENDS IN TREATMENT AMONG ELDERLY COLORECTAL CANCER PATIENTS IN THE US: EVIDENCE FROM LINKED SEER-MEDICARE DATA
Lang K1, Lines LM1, Lee DW2, Korn JR1, Vanness DJ3, Earle C4, Menzin J1
1Boston Health Economics, Inc, Waltham, MA, USA, 2GE Healthcare, Waukesha, WI, USA, 3University of Wisconsin-Madison, Madison, WI, USA, 4Harvard University, Boston, MA, USA

CN2: ECONOMIC EVALUATION OF EGFR-GUIDED TREATMENT IN ADVANCED REFRACTORY NON SMALL-CELL LUNG CANCER
Carlson JJ1, Garrison L1, Ramsey S2, Veenstra DL1
1University of Washington, Seattle, WA, USA, 2Fred Hutchinson Cancer Research Center, Seattle, WA, USA

CN3: COMPARISON OF THE COST EFFECTIVENESS OF SIX CYCLES OF TAXOTERE, DOXORUBICIN, CYCLOPHOSPHAMIDE (TAC) VERSUS SIX CYCLES OF FLUOROURACIL, DOXORUBICIN, CYCLOPHOSPHAMIDE (FAC) IN THE ADJUVANT SETTING OF NODE POSITIVE BREAST CANCER WITH PRIMARY AND SECONDARY G-CSF PROPHYLAXIS
Mittmann N1, Koo M1, Alloul K2, Trudeau M3
1Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 2sanofi-aventis Canada, Montreal, QC, Canada, 3Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

CN4: COSTS ASSOCIATED WITH NEUTROPENIA IN ELDERLY PATIENTS TREATED FIRST-LINE FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
Stokes ME1, Muehlenbein CE2, Marciniak MD2, Faries D2, Motabar S3, Buesching DP2, Gillespie TW4, Lipscomb J4, Knopf KB5
1United BioSource Corporation, Dorval, QC, Canada, 2Eli Lilly and Company, Indianapolis, IN, USA, 3United BioSource, Bethesda, MD, USA, 4Emory University and Veterans Affairs Medical Center, Atlanta, GA, USA, 5California Pacific Medical Center, San Francsico, CA, USA

Health Policy Research

HP1: A COMPARISON OF THREE TECHNOLOGY APPRAISAL SYSTEMS; NICE, SMC AND CADTH
Karia R1, Gani R2, Perard R1, Cann K2
1Heron Evidence Development Ltd, Letchworth Garden City, Hertfordshire, UK, 2Heron Evidence Development Ltd, Hertfordshire, UK

HP2: NHS REIMBURSEMENT OF NEW CANCER DRUGS: IS NICE GETTING NASTIER?
Mason AR1, Drummond M2
1University of York, York, N. Yorkshire, UK, 2University of York, York, Heslington, UK

HP3: PRIORITY SETTING FOR NEW TECHNOLOGIES: POSSIBLE DETERMINANTS AMONG THE WORKING POPULATION
Derycke H, Annemans L
1Ghent University, Gent, Belgium

HP4: 25 YEARS OF THE ORPHAN DRUG ACT: ANALYSIS OF THE NEW ORPHAN DRUGS APPROVED BETWEEN 1983 AND 2007
Rodriguez-Monguio R1, Visaria J2, Seoane-Vazquez E2
1University of Massachusetts, Amherst, MA, USA, 2The Ohio State University, Columbus, OH, USA

Research on Medicare Part D and Reimbursement Policies II

MD5: HEALTH CARE UTILIZATION BY MEDICARE ADVANTAGE BENEFICIARIES IN THE ERA OF THE MEDICARE PART D DRUG BENEFIT COVERAGE GAP
Delate T1, Raebel MA2, Ellis JL2, Bayliss EA2
1Kaiser Permanente Colorado, Aurora, CO, USA, 2Kaiser Permanente Colorado, Denver, CO, USA

MD6: INFLUENCE OF MEDICARE CLAIM-PAYING AGENTS' REIMBURSEMENT POLICY ON G-CSF CHOICE DURING FIRST CYCLE OF CHEMOTHERAPY FOR NON-HODGKIN'S LYMPHOMA PATIENTS
Pan X1, Brooks JM2, Wright KB1, Voelker MD1
1University of Iowa, Iowa City, IA, USA, 2USRDS Economic Special Study Center, The University of Iowa, Iowa City, IA, USA

MD7: DIFFERENTIAL TAKE-UP OF THE MEDICARE PART D PRESCRIPTION DRUG BENEFIT
Rabbani A1, Yin W1, Zhang JX1, Sun SX2, Alexander GC1
1University of Chicago, Chicago, IL, USA, 2Walgreens Health Services, Deerfield, IL, USA

MD8: THE IMPACT OF MEDICARE NEW DRUG BENEFIT (PART D) ON THE UTILIZATION OF PSYCHOTROPIC MEDICATIONS AND CONSEQUENT OUT OF POCKET EXPENDITURE FOR ELDERLY
Chen H1, Nwangwu A1, Aparasu R1, Sun SX2, Lee KY2
1University of Houston, Houston, TX, USA, 2Walgreens Health Services, Deerfield, IL, USA

Research on Patient Reported Outcomes Methods

PM1: RASCH RATING SCALE ANALYSIS OF THE EQ-5D USING THE 2003 MEDICAL EXPENDITURE PANEL SURVEY (MEPS)
Gu NY, Doctor JN
University of Southern California, Los Angeles, CA, USA

PM2: WHAT PATIENTS SAY VS. WHAT PATIENTS MEAN: QUALITATIVE RESEARCH IN PRO DEVELOPMENT
Lasch KE1, Marquis P1, Vigneux M2, Abetz L3, Arnould B2, Bayliss MS1, Crawford B1, Rosa K1, Scott J1
1Mapi Values, Boston, MA, USA, 2Mapi Values, Lyon, France, 3Mapi Values Limited, Bollington, UK

PM3: THE VALIDITY AND RELIABILITY OF A PARENT-CHILD DYAD APPROACH TO UTILITY AND QUALITY-OF-LIFE ASSESSMENT IN CHILDREN
Ungar WJ1, Boydell K1, Dell S1, Feldman BM1, Marshall DA2, Willan AR1, Wright J1
1The Hospital for Sick Children, Toronto, ON, Canada, 2McMaster University, Hamilton, ON, Canada

PM4: EVALUATION OF A THEORY OF GLOBAL HEALTH PREFERENCE FORMATION
Shaw JW1, Pickard AS1, Lin HW1, Cella D2, Trask PC3
1University of Illinois at Chicago, Chicago, IL, USA, 2Evanston Northwestern Healthcare, Evanston, IL, USA, 3Pfizer, Inc, New London, CT, USA


   
1:00PM-2:45PM LUNCH, EXHIBITS & POSTER PRESENTATIONS VIEWING - SESSION I
   
1:30PM-2:30PM EDUCATIONAL SYMPOSIUM - (Sponsored by IMS Health)
  Why Does Medication Noncompliance Persist?
Multiple Stakeholders Chart a Research Agenda for the 21st Century
The Symposium is free and open to all ISPOR delegates, no pre-registration required.

Sponsred by IMS IMS Logo

Few would argue with former Surgeon General C. Everett Koop’s assertion that “Drugs don’t work in patients who don’t take them.”  Noncompliance with prescribed medications cuts across all socio-demographic groups, therapy areas, and countries.  It reduces the effectiveness of treatments, contributes to 125,000 deaths, and costs the health care system over $175 billion each year. 

Yet despite a total of nearly 40,000 articles having been published on the topic of medication compliance since 1966, the latest examples from most therapy areas demonstrate that the problem persists—and patients don’t.  Why is this?  Have we studied the wrong questions?  Failed to translate good evidence into practice?  What are the clinical, administrative, and economic barriers?  Are there best practices that should be implemented more broadly? 

The 2008 IMS Health ISPOR Symposium will feature an interactive and dynamic discussion of these questions. The speakers will offer their perspectives on the body of research, why progress has been slow, and the keys to significantly improving medication compliance at the health system level. 

Moderator: Jonothan Tierce, CPhil, General Manager, IMS Health, Health Economics & Outcomes Research,
Falls Church, VA,USA.
Speakers:  Joshua S. Benner, PharmD, ScD, Principal, IMS Health, Health Economics & Outcomes Research,
Falls Church, VA, USA
Richard A. Feifer, MD, MPH, Vice President of Program Development, Care Enhancing Solutions,
Medco Health Solutions, Inc., Franklin Lakes, NJ, USA
2:45PM-3:45PM ISSUE PANELS - SESSION I (5 concurrent session)
 

CLINICAL OUTCOMES RESEARCH ISSUES

IP1: COMPARATIVE EFFECTIVENESS RESEARCH: BREAKING THE METHODS MOLD
Moderator: Sean Tunis MD, MSc, Executive Director, Center for Medical Technology Policy, Baltimore, MD, USA.
Panelist(s): Bryan Luce PhD, MBA, Senior Vice President, Science Policy, United BioSource Corporation, Bethesda, MD, USA; Brenda L. Gaydos PhD, Research Advisor, Eli Lilly and Company, Indianapolis, IN, USA; Michael Krams MD, Asst. Vice President, Wyeth Research, Collegeville, PA, USA.

HEALTH CARE POLICY DEVELOPMENT USING OUTCOMES RESEARCH ISSUES

IP2: IS NICE ALL THAT NASTY? COMPARISONS OF ACCESS TO CANCER THERAPY IN UK AND US HEALTH CARE
Moderator: Lee N Newcomer MD, Senior Vice President, Oncology, UnitedHealthcare, Edina, MN, USA.
Panelist(s): Mike F Drummond PhD, Professor of Health Economics, Centre for Health Economics, University of York, York, Heslington, UK; Scott Ramsey MD, PhD, Associate Member, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Dennis W Raisch PhD, Associate Center Director, Department of Veterans Affairs Cooperative Studies Program, Clinical Research Pharmacy Coordinating Center, Albuquerque, NM, USA.

CLINICAL OUTCOMES RESEARCH ISSUES
IP3: ESTABLISHING KEY PRINCIPLES FOR HEALTH TECHNOLOGY ASSESSMENT
Moderator: Sean D Sullivan PhD, RPh, Professor of Pharmacy and Public Health and Director, University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA.
Panelist(s): Naomi Aronson PhD, Executive Director, Blue Cross-Blue Shield Technology Evaluation Center, Chicago, IL, USA; Peter J. Neumann ScD, Professor, Tufts-New England Medical Center, Institute for Clinical Research and Health Policy Studies, Boston, MA, USA; Jill M. Sanders PhD, President and CEO, Canadian Agency for Drugs and Technologies in Health, Ottawa, ON, Canada.
 

IP4: NOW WHAT FOR GENOMICS? TURNING PROMISE INTO PRACTICE
Moderator: Clifford Goodman PhD, Senior Vice President, The Lewin Group, Falls Church, VA, USA.
Panelist(s): Deborah Marshall PhD, Vice President, i3 Innovus, Global Health Economics and Outcomes, Burlington, ON, Canada; Gurvaneet Randhawa MD, MPD, Medical Officer and Senior Advisor, Center for Outcomes and Evidence, Genomics & Personalized Medicine, Rockville, MD, USA; Emily S. Winn-Deen PhD, Vice President, Cepheid, Sunnyvale, CA, USA.

PATIENT-REPORTED OUTCOMES RESEARCH ISSUES

IP5: PATIENT-REPORTED OUTCOMES, HEALTH-STATE UTILITIES, OR STATED-PREFERENCES? SIMILARITIES, DIFFERENCES AND ROLES IN DEMONSTRATING PRODUCT VALUE
Moderator: A. Brett Hauber PhD, Senior Economist and Head, RTI Health Solutions, Health Preference Assessment, Research Triangle Park, NC, USA.
Panelist(s): Paul Kind PhD, Professor of Economics, Centre for Health Economics, University of York, York, Heslington, UK; William Furlong MSc, Research Coordinator, McMaster University and Health Utilities Inc, Hamilton, ON, Canada; F. Reed Johnson PhD*, Senior Fellow and Principal Economist, RTI International, Research Triangle Park, NC, USA.
3:45PM-4:00PM BREAK, EXHIBITS & POSTER PRESENTATIONS VIEWING - SESSION I
 
4:00PM-5:00PM PODIUM PRESENTATIONS - SESSION III (5 concurrent sessions)
 

Research in Adherence and Compliance I

AC1: THE ASSOCIATION BETWEEN IMPROVEMENTS IN DRUG ADHERENCE AND SHORT-TERM SERVICE UTILIZATION AND COSTS IN A MEDICAID POPULATION
Thiebaud P
Pfizer Health Solutions, New York, NY, USA

AC2: PATTERNS OF DIABETES MEDICATION AND TEST ADHERENCE IN A MEDICAID DISEASE MANAGEMENT PROGRAM
Demand M, Gutierrez PR, Thiebaud P
Pfizer Health Solutions, New York, NY, USA

AC3: DEPRESSIVE SYMPTOMATOLOGY, MEDICATION PERSISTENCE, AND ASSOCIATED HEALTH CARE COSTS IN OLDER ADULTS WITH INSOMNIA
Kulkarni AS1, Patel I2, Anderson RT3, Balkrishnan R1
1The Ohio State University College of Pharmacy, Columbus, OH, USA, 2The Ohio State University, Columbus, OH, USA, 3Wake Forest University School of Medicine, Winston Salem, NC, USA

AC4: THE COST OF NON-ADHERENCE TO ASTHMA TREATMENT GUIDELINES AMONG A LOW-INCOME COHORT
Said Q1, Waitzman NJ2
1University of Arkansas for Medical Sciences, Little Rock, AR, USA, 2University of Utah, Salt Lake City, UT, USA

Cardiovascular Disease Outcomes Research

CV1: EFFECTIVENESS OF COMBINED BETA-BLOCKER AND ACEI OR ARB THERAPY IN CHRONIC HEART FAILURE
Sharma M1, Deswal A2, Henderson L3, Desai R1, Chitnis A1, Petersen N4, Ashton C5, Johnson M4
1University of Houston, Houston, TX, USA, 2Baylor College of Medicine; Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA, 3University of Texas M.D.Anderson Cancer Center, Houston, TX, USA, 4Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA, 5University of Alabama, Birmingham, AL, USA

CV2: THE COST-EFFECTIVENESS OF CANDESARTAN IN THE TREATMENT OF CHRONIC HEART FAILURE (HF)- AN ASSESSMENT OF THE LOW LEFT VENTRICULAR EJECTION FRACTION (LOW-LVEF) TRIALS IN THE CANDESARTAN-IN-HEART-FAILURE-ASSESSMENT-OF-REDUCTION-IN-MORTALITY-AND-MORBIDITY (CHARM) TRIAL PROGRAMME
Levin LÅ1, Jørgensen E2, Eriksson B3, Swedberg K4, Paulsson T3
1Linköping University, Linköping, Sweden, 2AstraZeneca, Oslo, Norway, 3AstraZeneca, Södertälje, Sweden, 4Sahlgrenska Academy, Göteborg University, Gothenburg, Sweden

CV3: CLINICAL AND ECONOMIC OUTCOMES ASSOCIATED WITH BLEEDING DURING CORONARY ARTERY BYPASS GRAFT SURGERY AMONG ELDERLY AMERICANS
Ganz ML1, Joshi AV2, Wang Q3, Wilke CT4, Lee WC3, Pashos CL1
1Abt Associates, Inc, Lexington, MA, USA, 2Novo Nordisk Inc, Princeton, NJ, USA, 3Abt Associates, Inc, Bethesda, MD, USA, 4University of Illinois at Chicago, Chicago, IL, USA

CV4: CAN TWO A'S RESULT IN A FAILURE?: EFFECT OF ASPIRIN ON THE RISK OF HEART FAILURE HOSPITALIZATIONS IN CHF PATIENTS ON ACE INHIBITORS.
Shah DH, Parikh NM, Kamble PS, Chen H, Johnson M
University of Houston, Houston, TX, USA

Diabetes Outcomes Research

DB1: REAL-WORLD SIX MONTH OUTCOMES OF PATIENTS INITIATING EXENATIDE IN A PRIMARY CARE ELECTRONIC MEDICAL RECORD DATABASE
Brixner D1, McAdam-Marx C1, Ye X1, Boye KS2, Schroeder B3, Fabunmi R3
1The University of Utah College of Pharmacy, Salt Lake City, UT, USA, 2Eli Lilly and Company, Indianapolis, IN, USA, 3Amylin Pharmaceuticals, Inc, San Diego, CA, USA

DB2: COST-EFFECTIVENESS ANALYSIS OF PREGABALIN FOR THE MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY IN MEXICO
Arreola-Ornelas H1, Dorantes-Aguilar J1, García-Mollinedo MDL2, Rosado-Buzzo AA2, Mould-Quevedo J3, Davila-Loaiza G3
1Fundación Mexicana para la Salud, Funsalud, Mexico City, Mexico, 2Links & Links S.A. de C. V, Mexico City, Mexico, 3Pfizer Mexico, Mexico City, Mexico

DB3: REAL-WORLD ANALYSIS OF PERCENT OF PATIENTS WITH TYPE 2 DIABETES ACHIEVING GLYCEMIC GOAL WITH INSULIN GLARGINE
Misurski D1, Schroeder B2, Wade R3, Quimbo R3, Nielsen L2, Fabunmi R2, Wintle M2
1Eli Lilly and Company, Indianapolis, IN, USA, 2Amylin Pharmaceuticals, Inc, San Diego, CA, USA, 3HealthCore, Inc, Wilmington, DE, USA

DB4: RETROSPECTIVE STUDY OF TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS NOT OPTIMALLY CONTROLLED BY METFORMIN MONOTHERAPY
He J, Neslusan C Johnson & Johnson Pharmaceutical Services L.L.C, Raritan, NJ, USA

Drug Use Research I

DU1: DEMOGRAPHIC RISK FACTORS FOR STROKE RELATED AMBULATORY CARE UTILIZATION: ANALYSIS OF UNITED STATES NATIONAL DATA 2000-2005
Karve S, Levine D, Balkrishnan R
The Ohio State University, Columbus, OH, USA

DU2: DOES COMMUNITY-BASED HEALTH INSURANCE IMPROVE ACCESS TO DRUGS AND HEALTH CARE FOR THE POOREST IN AFRICA?
Souares A1, Savadogo G2, Gnawali DP1, Sauerborn R1
1Heidelberg University, Heidelberg, BadenWürttemberg, Germany, 2Centre de Recherche en Santé de Nouna, Nouna, Kossi, Burkina Faso

DU3: CALIFORNIA WILDFIRES AND THEIR IMPACT ON MEDICATION ACQUISITION
Hutchins DS1, Liberman JN2, Tong W1, Berger JE3
1CVS Caremark, Scottsdale, AZ, USA, 2CVS Caremark Corporation, Hunt Valley, MD, USA, 3CVS|Caremark Inc, Northbrook, IL, USA

DU4: PRESCRIPTION DRUG UTILIZATION AMONG A NATIONALLY REPRESENTATIVE SAMPLE OF MEDICARE BENEFICIARIES WITH HEART FAILURE
Bain KT1, Richardson D2, Liao D2, Diamond J3, Novielli KD2, Goldfarb NI3
1excelleRx, Inc, Philadelphia, PA, USA, 2Jefferson Medical College, Philadelphia, PA, USA, 3Thomas Jefferson University, Philadelphia, PA, USA

Research on Outcomes Research Methods

OM1: VALIDATING A SURVEY INSTRUMENT USING NONPARAMETRIC ITEM RESPONSE THEORY – APPLICATION OF KERNEL REGRESSION
Lin HW1, Pickard AS1, Karabatsos G2, Mahady GB1, Crawford SY1, Popovich NG1
1College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA, 2College of Education, University of Illinois at Chicago, Chicago, IL, USA

OM2: USING VALUE OF INFORMATION METHODOLOGY TO DETERMINE THE SAMPLE SIZE FOR A RANDOMIZED CLINICAL TRIAL FROM AN INDUSTRY PERSPECTIVE
Willan AR
SickKids Research Insitute, Toronto, ON, Canada

OM3: WAS IT NICE FOR YOU? ESTIMATING SUBGROUP QUALITY OF LIFE TARIFFS FROM CONJOINT ANALYSES: RESULTS FROM A BEST-WORST SCALING STUDY
Flynn TN1, Louviere JJ2, Peters TJ1, Coast J3
1University of Bristol, Bristol, UK, 2University of Technology, Sydney, NSW, Australia, 3University of Birmingham, Birmingham, UK

OM4: LONG-TERM COST-EFFECTIVENESS OF A DIABETES RISK SCORE IN CLINICAL PRACTICE
Sullivan SD1, Garrison LP1, Rinde H2, Kolberg J3, Moler E3, Urdea M4
1University of Washington, Seattle, WA, USA, 2BioBridge Strategies, Binningen, Switzerland, 3Tethys Bioscience Inc, Emeryville, CA, USA, 4Tethys Bioscience, Inc, Emeryville, CA, USA

5:15PM-6:15PM PODIUM PRESENTATIONS - SESSION IV (5 concurrent sessions)
 

Research in Adherence and Compliance II

AC5: ORAL ANTIDIABETIC MEDICATION ADHERENCE AND HEALTH CARE COSTS AND UTILIZATION AMONG MEDICAID-ENROLLED TYPE 2 DIABETES PATIENTS NEWLY STARTING MONOTHERAPY
Shenolikar R1, Balkrishnan R2
1Glaxo SmithKline, Columbus, OH, USA, 2The Ohio State University, Columbus, OH, USA

AC6: ASSOCIATION OF NONCOMPLIANCE WITH DIABETES CARE GUIDELINES AND DISEASE BURDEN IN A CALIFORNIA MEDICAID TYPE 2 DIABETES MELLITUS POPULATION
Nichol MB1, Knight TK1, Wu J1, Priest JL2, Cantrell CR2
1University of Southern California, Los Angeles, CA, USA, 2GlaxoSmithKline, Research Triangle Park, NC, USA

AC7: COMPARING ADHERENCE TO FIXED DOSE COMBINATION VERSUS MULTI-PILL COMBINATION THERAPIES AMONG PATIENTS WITH DYSLIPIDEMIA IN A MANAGED CARE POPULATION
Balu S1, Simko RJ1, Burge RT1, Quimbo R2, Cziraky MJ2
1Abbott Laboratories, Abbott Park, IL, USA, 2HealthCore, Inc, Wilmington, DE, USA

AC8: ASSOCIATION OF MEASURES OF MEDICATION ADHERENCE AND SEVERE RELAPSES WITH MULTIPLE SCLEROSIS DISEASE-MODIFYING THERAPY
Dickson M1, Kozma C2, Okuda DT3, Fincher C4, Meletiche D4
1University of South Carolina, College of Pharmacy, Columbia, SC, USA, 2University of South Carolina, West Columbia, SC, USA, 3University of California, San Francisco, San Francisco, CA, USA, 4EMD Serono, Inc, Rockland, MA, USA

Drug Use Research II

DU5: IMPACT OF FORMULARY RESTRICTIONS ON ADHERENCE TO SECOND GENERATION ANTIPSYCHOTICS
Zeng F1, Leslie RS1, Patel BV1, Chen CC2, Kim E2, Knoth R2, Tran QV3
1MedImpact Healthcare Systems, Inc, San Diego, CA, USA, 2Bristol-Myers Squibb, Plainsboro, NJ, USA, 3Otsuka America Pharmaceutical Inc, Rockville, MD, USA

DU6: ASSESSMENT OF DRUG UTILIZATION PATTERNS AND COSTS FOR ERYTHROPOIETIC STIMULATING AGENTS IN ELDERLY PATIENTS WITH CHRONIC KIDNEY DISEASE
Lafeuille MH1, Lefebvre P1, Bookhart B2, Laliberte F1, Bailey R2, Corral M2, Piech CT2
1Groupe d'analyse, Ltee, Montreal, QC, Canada, 2Ortho Biotech Clinical Affairs, LLC, Bridgewater, NJ, USA

DU7: NATIONAL ESTIMATES AND DETERMINANTS OF DEPRESSION AND ANTIDEPRESSANT TREATMENT IN CANCER PATIENTS IN THE UNITED STATES, 2004-2005
Sankaranarayanan J, Smith LM, Meza J, Burke WJ
University of Nebraska Medical Center, Omaha, NE, USA

DU8: THE EFFECT OF THREE-TIER FORMULARY ADOPTION FOR ALPHA-BLOCKERS ON DRUG UTILIZATION IN THE DEPARTMENT OF DEFENSE
Devine JW, Conrad RC, Tiller KW
Department of Defense Pharmacoeconomic Center, Fort Sam Houston, TX, USA

Infectious Disease Outcomes Research

IN1: C. ALBICANS AND C. GLABRATA BLOODSTREAM INFECTIONS IN ADULTS: OUTCOMES AND ASSOCIATED COSTS
Grussemeyer CA1, Friedman JY1, Spalding JR2, Benjamin DK3, Moran C3, Reed SD1
1Duke Clinical Research Institute, Durham, NC, USA, 2Astellas Pharma US, Deerfield, IL, USA, 3Duke University Medical Center, Durham, NC, USA

IN2: UPPER RESPIRATORY ILLNESS AND EMPLOYEE PRODUCTIVITY – RESULTS FROM THE CHILD AND HOUSEHOLD INFLUENZA-ILLNESS AND EMPLOYEE FUNCTION (CHIEF)
Palmer L1, Nichol KL2, Johnston S1, Mahadevia PJ3, Rousculp MD3
1Thomson Healthcare, Inc, Washington, DC, USA, 2Veterans Affairs Medical Center, Minneapolis, MN, USA, 3MedImmune, Inc, Gaithersburg, MD, USA

IN3: A MICROSIMULATION OF THE COST-EFFECTIVENESS OF MARAVIROC FOR ANTIRETROVIRAL TREATMENT-EXPERIENCED HIV-INFECTED INDIVIDUALS
Chancellor JV1, Kuehne FC2, Mollon P3, Louie M4, Powderly WG5
1i3 Innovus, Uxbridge, Middlesex, UK, 2PharmacoConsult, Wanzleben-Buch, Germany, 3Pfizer Limited, Sandwich, Kent, UK, 4Pfizer Inc, New York, NY, USA, 5University College Dublin, Dublin, Ireland

IN4: COST-EFFECTIVENESS OF DORIPENEM IN THE TREATMENT OF NOSOCOMIAL PNEUMONIA
McGarry LJ1, Merchant S2, Pawar V1, Delong K1, Thompson D1, Akhras K2, Ingham M2, Weinstein MC3
1Innovus Research, Inc, Medford, MA, USA, 2Johnson & Johnson Pharmaceutical Services, L.L.C, Raritan, NJ, USA, 3Harvard University, Boston, MA, USA

Patient-Reported Outcomes Research

PR1: VARIABILITY OF HEALTH UTILITIES INDEX MARK 3 (HUI3) MEASUREMENTS DURING TREATMENT FOR ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDHOOD
Rae CS1, Furlong W2, De Pauw S1, Barr RD1, Gelber RD3, Sallan S3
1McMaster University, Hamilton, ON, Canada, 2McMaster University and Health Utilities Inc, Hamilton, ON, Canada, 3Harvard University, Boston, MA, USA

PR2/PCN75: BURDEN OF IMMUNE THROMBOCYTOPENIC PURPURA ON HEALTH-RELATED QUALITY OF LIFE
Mathias S1, Tarantino M2, Guo M3, Gao S3
1Health Outcomes Solutions, Winter Park, FL, USA, 2University of Illinois College of Medicine-Peoria, Peoria, IL, USA, 3Amgen, Thousand Oaks, CA, USA

PR3: IMPACT OF UNCONTROLLED PEDIATRIC ASTHMA ON HEALTH-RELATED QUALITY OF LIFE (HRQOL)
Dean BB1, Calimlim B1, Aguilar D1, Sacco P2, Maykut R2, Tinkelman D3
1Cerner LifeSciences, Beverly Hills, CA, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 3National Jewish Medical and Research Center, Denver, CO, USA

PR4: EVALUATION OF IMPACT OF ORAL TOPOTECAN ON HEALTH-RELATED QUALITY OF LIFE IN RELAPSED SMALL CELL LUNG CANCER
Duh MS1, Pickard AS2, Chen L1, Antras L1, Cella D3, Neary MP4, O'Brien ME5
1Analysis Group, Inc, Boston, MA, USA, 2College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA, 3Evanston Northwestern Healthcare, Evanston, IL, USA, 4GlaxoSmithKline, Collegeville, PA, USA, 5Royal Marsden Hospital, Sutton, UK

Women's Health Outcomes Research

WH1: EXPOSURE TO CONTRAINDICATED AND OTHER POTENTIALLY DANGEROUS MEDICATIONS DURING PREGNANCY: A POPULATION BASED STUDY IN ITALY
Gagne JJ, Maio V, Berghella V, Louis DZ, Gonnella JS
Jefferson Medical College, Philadelphia, PA, USA

WH2: DISABILITY AND ASSOCIATED COSTS AMONG WOMEN WITH EMPLOYER-SPONSORED INSURANCE AND NEWLY DIAGNOSED BREAST CANCER
Meadows E1, Johnston S2, Cao Z3, Foley K4, Pohl G1, Johnston JA1, Ramsey SD5
1Eli Lilly and Company, Indianapolis, IN, USA, 2Thomson Healthcare, Inc, Washington, DC, USA, 3Thomson Healthcare, Cambridge, MA, USA, 4Thomson Medstat, Philadelphia, PA, USA, 5Fred Hutchinson Cancer Research Center, Seattle, WA, USA

WH3: CLINICAL AND ECONOMIC OUTCOMES AMONG WOMEN USING LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM (LNG-IUS)
Yu AP1, Wu E1, Perrson B1, Chang J2, Costales AC2, Gricar JA3
1Analysis Group, Inc, Boston, MA, USA, 2Bayer HealthCare Pharmaceuticals, Inc, Wayne, NJ, USA, 3Independent Health Care Consultant, New York, NY, USA

WH4: PROBIOTICS IN PREGNANCY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE SAFETY OF LACTOBACILLUS, BIFIDOBACTERIUM AND SACCHAROMYCES
Dugoua JJ1, Zhu X1, Chen X1, Koren G2, Machado M1, Einarson TR1
1University of Toronto, Toronto, ON, Canada, 2Hospital for Sick Children, Toronto, ON, Canada

6:15PM-7:00PM ISPOR ANNUAL BUSINESS MEETING
   

Call To Order: Diana Brixner PhD, 2007-2008 President

Executive Director’s Report: Marilyn Dix Smith PhD, ISPOR Executive Director

Treasurer’s Report: Karen Rascati PhD, ISPOR Treasurer

Audit Report: Richard Willke, Chair, ISPOR Audit Committee

Value In Health Editor-In-Chief Report: Josephine Mauskopf PhD, Value in Health Editor-in-Chief

ISPOR CONNECTIONS Editor-In-Chief Report: Steven E. Marx PharmD, MS

Member Open Discussion: ISPOR Members

New Business: Diana Brixner PhD, 2007-2008 President
6:15PM-7:15PM AUTHOR PRESENTATION HOUR - POSTER PRESENTATION - SESSION I
     
6:15PM-8:00PM EXHIBITORS' OPEN HOUSE RECEPTION & POSTER PRESENTATION - SESSION I

Contact ISPOR @ info@ispor.org  |  View Legal Disclaimer
©2008 International Society for Pharmacoeconomics and Outcomes Research. All rights reserved under International and Pan-American Copyright Conventions. 
Website design by Eagle Systems USA, Inc.